Literature DB >> 2898029

Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia.

T Matsuo1, M Tomonaga, J M Bennett, K Kuriyama, F Imanaka, A Kuramoto, N Kamada, M Ichimaru, S C Finch, A V Pisciotta.   

Abstract

The concordance rate for diagnoses of atomic bomb-related cases of leukemia in Nagasaki was determined using the French-American-British (FAB) classification for acute leukemias and myelodysplastic syndromes (MDS). Two Radiation Effects Research Foundation (RERF) hematologists and one of the members (JMB) of the FAB cooperative group reviewed independently the peripheral blood and/or bone marrow smears from 193 people with leukemia or a related disorder. There was 85% agreement in the identification of types and subtypes of acute leukemia. There was almost complete agreement for the diagnoses of non-FAB disorders (chronic myeloid leukemia (CML), adult T-cell leukemia (ATL) and others) resulting in overall concordance of 88.2%. The present study suggests that the previously established leukemia types for about a quarter of the cases of acute leukemia and related disorders except CML should be changed. Considerable numbers of cases of ATL and MDS were involved in this series. The frequency of the former disease was not high in the high-dose irradiated group, but that of the latter was considerably high. All subtypes of AML except M3 and M6 were present in the high-dose group. The striking difference in CML incidence between Nagasaki and Hiroshima may continue to be a problem in relation to biological response to radiation exposure.

Entities:  

Mesh:

Year:  1988        PMID: 2898029

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  6 in total

Review 1.  Late effect of atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes.

Authors:  Hideki Tsushima; Masako Iwanaga; Yasushi Miyazaki
Journal:  Int J Hematol       Date:  2012-02-28       Impact factor: 2.490

2.  Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.

Authors:  T Radivoyevitch; R K Sachs; R P Gale; R J Molenaar; D J Brenner; B T Hill; M E Kalaycio; H E Carraway; S Mukherjee; M A Sekeres; J P Maciejewski
Journal:  Leukemia       Date:  2015-09-22       Impact factor: 11.528

Review 3.  Histologic verification of leukemia, myelodysplasia, and multiple myeloma diagnoses in patients in Ukraine, 1987-1998.

Authors:  Irina Dyagil; Mircea Adam; Gilbert W Beebe; J David Burch; Svetlana N Gaidukova; Daniel Gluzman; Natalia Gudzenko; Victor Klimenko; LoAnn Peterson; Robert F Reiss; Stuart C Finch
Journal:  Int J Hematol       Date:  2002-07       Impact factor: 2.490

Review 4.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

5.  The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001.

Authors:  Wan-Ling Hsu; Dale L Preston; Midori Soda; Hiromi Sugiyama; Sachiyo Funamoto; Kazunori Kodama; Akiro Kimura; Nanao Kamada; Hiroo Dohy; Masao Tomonaga; Masako Iwanaga; Yasushi Miyazaki; Harry M Cullings; Akihiko Suyama; Kotaro Ozasa; Roy E Shore; Kiyohiko Mabuchi
Journal:  Radiat Res       Date:  2013-02-11       Impact factor: 2.841

6.  Incidence of lymphoid neoplasms among atomic bomb survivors by histological subtype, 1950 to 1994.

Authors:  Megumu Fujihara; Ritsu Sakata; Noriaki Yoshida; Kotaro Ozasa; Dale L Preston; Kiyohiko Mabuchi
Journal:  Blood       Date:  2022-01-13       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.